Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Andrea Lucania

Nurse Practitioner Tampa, FL Nurse Practitioner

NPI 1831570183 CMS profile 10476627

10940 Sheldon Rd, Tampa, FL 33626

Open in the dashboard

General payments

$5,548

223 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Andrea Lucania of Tampa, FL is reported in the CMS Open Payments database as having received $5,548 across 223 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,564 61
2024 General $1,292 47
2023 General $921 38
2022 General $1,017 37
2021 General $753 40

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrea Lucania
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Andrea Lucania were reported at $1,564. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Andrea Lucania Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $753 $135 $40–$426 $132
2022 $1,017 $152 $48–$470 $149
2023 $921 $166 $54–$529 $160
2024 $1,292 $173 $55–$556 $164
2025 $1,564 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Regeneron Healthcare Solutions, Inc. $888 23 payments
  2. AstraZeneca Pharmaceuticals LP $862 39 payments
  3. Genzyme Corporation $732 25 payments
  4. GlaxoSmithKline, LLC. $717 36 payments
  5. CSL Behring $506 24 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $360 12 payments
  7. Pfizer Inc. $265 15 payments
  8. Novartis Pharmaceuticals Corporation $228 9 payments
  9. Amgen Inc. $174 7 payments
  10. Aimmune Therapeutics, Inc. $140 2 payments
  11. Other $675 31 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,361 221 payments
  2. Honoraria $125 1 payment
  3. Education $62 1 payment
Products named General payments · program years 2021–2025
  1. DUPIXENT Immunology $1,347 49 payments
  2. DUPIXENT Inflammation And Immunology $577 16 payments
  3. TRELEGY ELLIPTA $442 23 payments
  4. Hizentra $439 21 payments
  5. FASENRA $438 22 payments
  6. CUVITRU $328 11 payments
  7. DUPIXENT Immunology And Inflammation $311 7 payments
  8. NUCALA $275 13 payments
  9. EUCRISA $254 14 payments
  10. TEZSPIRE $212 10 payments
  11. Other $1,474 61 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

272

Median for Nurse Practitioner: 389

Drug cost

$123,925

Median for Nurse Practitioner: $21,885

Branded share of claims

30.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Syringe Dupilumab Brand 15 $55,823
Xolair Omalizumab Brand 13 $37,066
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 22 $17,904
Breo Ellipta Fluticasone/Vilanterol Brand 17 $7,900
Azelastine Hcl Generic 59 $2,081
Ipratropium Bromide Generic 39 $1,215
Fluticasone Propionate Generic 43 $882
Montelukast Sodium Generic 33 $408
Levocetirizine Dihydrochloride Generic 14 $385
Albuterol Sulfate Hfa Albuterol Sulfate Brand 17 $260

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $259
  • Regeneron Healthcare Solutions, Inc. $168
$428 15 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $151
$151 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $132
$132 — —
Hizentra
  • CSL Behring $122
$122 — —
TEZSPIRE
  • Amgen Inc. $54
  • AstraZeneca Pharmaceuticals LP $51
$106 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

223 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record